New biomarker in breast and prostate cancer may help identify patients who will respond to taxanes

New biomarker in breast and prostate cancer may help identify patients who will respond to taxanes
New biomarker in breast and prostate cancer may help identify patients who will respond to taxanes

Researchers have identified a novel genetic biomarker responsible for the progression of many breast and prostate cancers. The finding could bolster efforts to better identify patients who respond to certain types of chemotherapy drugs that attack the most aggressive forms of cancer. Their findings were published in Scientific Reports (2015; doi:10.1038/srep12136).

"Understanding and identifying biomarkers is a vital step toward cancer research and care," said lead author Michael Freeman, PhD, vice chair of research in the Cedars-Sinai Department of Surgery in Los Angeles, California. "New profiling strategies exemplified by this study will ultimately improve our ability to treat cancer patients."

The newly identified biomarker, diaphanous-related formin-3 or DIAPH3, participates in a protein interaction that makes cells rigid. The study found that when this biomarker is lost or lowered, cells become deformable, squeezing through tissue spaces, causing disease growth or progression. This phenomenon is known as an amoeboid phenotype.

Researchers can utilize this knowledge to better identify patients who will respond to taxanes, common chemotherapy drugs typically given to patients with the most aggressive forms of cancer. The DIAPH3 protein network may indicate sensitivity to taxanes in human tumors. Taxanes work by damaging protein structures in cancer cells.

This is the first study to identify a targeting strategy for tumor cells that exhibit amoeboid properties.

"By identifying cancer biomarkers, then customizing treatment plans for individuals based on this genetic information, we can greatly improve the effectiveness of cancer therapies," said Shlomo Melmed, MD, senior vice president of Academic Affairs and director of the Burns and Allen Research Institute. "This customized plan replaces a one-size-fits-all approach to cancer treatment."

Next steps involve the development of a biomarker tool that will allow researchers to test these findings prospectively in patients.

Loading links....
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs